Rebecca Richards-­Kortum and Tomasz Tkaczyk of Rice University in the U.S. propose to develop a plug­-and-­sense read-out and signal transduction (ROST) component for point­-of-­care devices that will be palm­-sized, producible for under $10, and with new interrogation units can be rearranged within the universal fixture to accommodate new sample platforms.

Ross Durland and colleagues at AM Biotechnologies, LLC in the U.S. propose to develop X-­aptamers for detecting and quantifying protein biomarkers for neglected diseases. X­-aptamers are modified nucleic acids that tightly bind to specific targets and remain stable at high temperature and humidity. AM Biotech will enhance its process for rapidly identifying X-­aptamers that will be integrated into a point­-of-­care platform for diagnosing many diseases.

Donald Chickering and a team at Seventh Sense Biosystems in the U.S. are developing its Touch Activated Phlebotomy (TAP) platform to enable one­-step blood collection in a safe, painless, and convenient manner. The device uses an integrated system of microneedles and vacuum capture of a blood sample for downstream analysis. TAP has the potential to expand access to diagnostic testing into underserved and hard-­to-­sample populations, while also improving safety and ease of collection.

Andrew Ellington of the University of Texas at Austin in the U.S. proposes to improve enzyme­-free DNA circuits by engineering circuit sensitivity and selectivity, ultimately creating multi­-layered circuits that greatly amplify signal inputs. These robust amplifiers could be modularly introduced into a variety of point­-of-­care diagnostics.